The United Kingdom and the United States have signed a significant bilateral deal that will guarantee no tariffs on UK pharmaceutical exports being sold in the US market.
Agreement Details of the Deal
As part of the deal, the UK has agreed to increase expenditure on pharmaceuticals through the NHS. This commitment guarantees that import taxes on these vital exports will stay at nothing for a timeframe of three years.
This agreement is in response to previous threats to significantly raise duties on branded pharmaceutical imports, with increases discussed as high as double the cost.
"This arrangement between the Britain strengthens the international landscape for innovative medicines and introduces much-needed balance to U.S.–U.K. drug exports," a release said.
Commercial Significance
Drugs constitute one of the UK's largest goods shipped to the United States, which is by far the biggest market for major companies like GSK and AstraZeneca.
Statistics indicate that in the one-year period to the end of last September, the UK sold drugs totaling billions to the US. This value made up a significant portion of British export trade in that period.
"This deal protects work, stimulates capital expenditure and sets the stage for the UK to become a worldwide center for biotech and pharma," the Business and Trade Secretary remarked.
Detailed NHS Changes
The agreement involves several notable pledges from the British government:
- Revised Affordability Limit: The UK will lift the cost ceiling at which it deems new medicines to be too expensive by 25%.
- Higher Drug Budget: There is a target to raise overall public funding on drugs from 0.3 percent of Gross Domestic Product to 0.6 percent over the next decade.
- Rebate Cap: The sum manufacturers must return to the NHS to stay within budget will be capped at fifteen percent. Last year, refunds topped twenty percent.
Industry Background
The deal takes place against a protracted row between the drug companies and the British authorities over medicine costs and NHS adoption.
These tensions were intensified by claims that US patients were charged several times more for the equivalent treatments than consumers in the other developed nations.
Recently, several large pharmaceutical investments in the UK have been halted or abandoned, while substantial investments have been announced toward US facilities.
A senior figure acknowledged that the NHS had to increase expenditure on medicines, noting that its expenditure on drugs had declined as a proportion of its total funding over the previous ten-year period.
